Overview
Plain-language guide
Designed and approved for specific uses that include Short bowel syndrome.
It copies an intestinal growth signal that helps the bowel lining absorb nutrients and fluid.
Clinical mechanism
Activates GLP-2 receptors to support intestinal mucosal growth and absorption.
Applications
Human evidence
Multiple human studies and regulatory review support at least one product-specific indication.
Tier 1Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Regulatory status
Approved. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Known but Manageable Risks
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Takeda · Approved. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- Evidence must be interpreted by indication and product label.
- Approval does not establish safety or efficacy for off-label or compounded copies.
Last reviewed
August 5, 2026 · Reviewed